|
|
 |
|
Viewing report
|
|
|
|
U.S. Emerging Psoriasis Therapeutics Markets
Frost & Sullivan, June 2001
Targeted Immunotherapies Define Future of the Field
Psoriasis affects more than seven million people in the United States. Although immunosuppresants have been used to treat psoriasis for some time, these drugs often subdue the entire immune system, sometimes causing
serious side effects. As scientists begin to unravel the genetic and immunological mysteries of psoriasis, a new wave of immunotherapies are being developed that will target specific psoriasis-related immunological
pathways without compromising the body's defense mechanisms.
This Frost & Sullivan research investigates the status of drugs in development and assesses their role in the future treatment regimen for psoriasis. It analyzes potential markets for monoclonal antibodies and for other emerging products. By discussing market drivers and restraints and by presenting accurate revenue forecasts, this report offers its users an important guide to the future of a largely untapped field.
Manufacturers Must Encourage Dermatologists to Utilize New Therapies
Drug companies may find it challenging to persuade dermatologists to prepare their practices for some of these new products, says the research's author. Dermatologists are used to prescribing topical products. Few prescribe oral medications on a regular basis, administer injections, or manage intravenous infusions. Yet it is through these methods that new immunotherapies will be administered.
Dermatologists whose practices focus on lucrative cosmetic dermatology may also be reluctant to undertake medical procedures, especially if reimbursement is problematic. Dermatologists need to be trained and
motivated to invest in the necessary equipment required to administer these new drugs. This report identifies challenges that participants will face and provides expert recommendations, empowering your company to overcome hurdles and overtake the competition.
Strategic Partnerships Could Help Small Firms Increase Market Share
Many of the new psoriasis drugs are being developed by small biopharmaceutical companies that lack the resources to manage drug commercialization, says the author. Often these companies have built up an expertise in a specific pharmaceutical sector but are unfamiliar with psoriasis markets. For many of these companies, the answer might be to partner with larger drug firms, which can provide financial assistance for adequate product development and commercialization. This study surveys the competitive field and pinpoints winning strategies, helping your company develop an effective
business plan.
Customers who bought this item also bought
North American Psoriasis and Psoriatic Arthritis Markets
Psoriasis - Biologics are Yet to Make Topical Treatments Obsolete
Therapeutic Clinical Intelligence - Psoriasis
Commercial Insight: Psoriasis - Intellectual property drives growth
Psoriasis - Biologics Impact Treatment Regimes Across The Globe
Competitor Analysis: Psoriasis
Psoriasis Market Forecast
Dermatology Psoriasis
Commercial and Pipeline Insight: Psoriasis - Anti-TNFs Lead Another Indication
Pipeline and Commercial Perspectives: Psoriasis and Atopic Dermatitis - Reimbursement the key as biologics and TIMs transform disease markets
US market size for psoriasis medications by prevalence of moderate-to-severe disease in 2001 forecast to 2006, with forecast patient numbers, dollar sales and operating profits for Genentech Inc's new Xanelim psoriasis drug in 2004 to 2006
Alzheimer Disease - New Drugs, Markets and Companies
|
|
|
|
